Preclinical rationale for combining radiation therapy and immunotherapy beyond checkpoint inhibitors (i.e., CART)

James P. Flynn, Mark H. O'Hara, Saumil Gandhi

Research output: Contribution to journalReview article

12 Citations (Scopus)

Abstract

An increasing appreciation for the role of the immune system in targeting cancer cells over the last decade has led to the development of several immunomodulatory agents aimed at enhancing the systemic antitumor immune response. One such method is the use of T cells that are genetically engineered to express chimeric antigen receptors (CARs). The remarkable success of this approach in advanced hematologic malignancies has garnered much enthusiasm for using this novel tool in treating other cancers. However, multiple challenges have hampered the application of this therapy to a broader set of solid tumors, most notably lung cancer. Immunotherapy has already shown great success in lung cancer, and is now the first-line treatment in PD-L1 expressing metastatic disease. Given the mounting evidence that radiation therapy plays a crucial role in amplifying the immune response elicited by immunomodulatory agents, there is potential for radiation to help in overcoming some of these challenges. In this review, we describe the basic principles of CAR T cell therapy and examine its successes and challenges to date. We then discuss the preclinical and clinical data supporting the use of radiation with immunomodulatory agents with a focus on preclinical rationale for combining CAR T cells and radiation therapy in future experiments with a focus on lung cancer.

Original languageEnglish (US)
Pages (from-to)159-168
Number of pages10
JournalTranslational Lung Cancer Research
Volume6
Issue number2
DOIs
StatePublished - Apr 1 2017

Fingerprint

Antigen Receptors
Immunotherapy
Lung Neoplasms
Radiotherapy
Cell- and Tissue-Based Therapy
Radiation
Neoplasms
Hematologic Neoplasms
Immune System
T-Lymphocytes
Therapeutics

Keywords

  • Chimeric antigen receptor T cells (CAR T cells)
  • Immunotherapy
  • Radiation therap

ASJC Scopus subject areas

  • Oncology

Cite this

Preclinical rationale for combining radiation therapy and immunotherapy beyond checkpoint inhibitors (i.e., CART). / Flynn, James P.; O'Hara, Mark H.; Gandhi, Saumil.

In: Translational Lung Cancer Research, Vol. 6, No. 2, 01.04.2017, p. 159-168.

Research output: Contribution to journalReview article

@article{eb3bd11bacb041869dee842ec5a93c78,
title = "Preclinical rationale for combining radiation therapy and immunotherapy beyond checkpoint inhibitors (i.e., CART)",
abstract = "An increasing appreciation for the role of the immune system in targeting cancer cells over the last decade has led to the development of several immunomodulatory agents aimed at enhancing the systemic antitumor immune response. One such method is the use of T cells that are genetically engineered to express chimeric antigen receptors (CARs). The remarkable success of this approach in advanced hematologic malignancies has garnered much enthusiasm for using this novel tool in treating other cancers. However, multiple challenges have hampered the application of this therapy to a broader set of solid tumors, most notably lung cancer. Immunotherapy has already shown great success in lung cancer, and is now the first-line treatment in PD-L1 expressing metastatic disease. Given the mounting evidence that radiation therapy plays a crucial role in amplifying the immune response elicited by immunomodulatory agents, there is potential for radiation to help in overcoming some of these challenges. In this review, we describe the basic principles of CAR T cell therapy and examine its successes and challenges to date. We then discuss the preclinical and clinical data supporting the use of radiation with immunomodulatory agents with a focus on preclinical rationale for combining CAR T cells and radiation therapy in future experiments with a focus on lung cancer.",
keywords = "Chimeric antigen receptor T cells (CAR T cells), Immunotherapy, Radiation therap",
author = "Flynn, {James P.} and O'Hara, {Mark H.} and Saumil Gandhi",
year = "2017",
month = "4",
day = "1",
doi = "10.21037/tlcr.2017.03.07",
language = "English (US)",
volume = "6",
pages = "159--168",
journal = "Translational Lung Cancer Research",
issn = "2226-4477",
publisher = "Society for Translational Medicine (STM)",
number = "2",

}

TY - JOUR

T1 - Preclinical rationale for combining radiation therapy and immunotherapy beyond checkpoint inhibitors (i.e., CART)

AU - Flynn, James P.

AU - O'Hara, Mark H.

AU - Gandhi, Saumil

PY - 2017/4/1

Y1 - 2017/4/1

N2 - An increasing appreciation for the role of the immune system in targeting cancer cells over the last decade has led to the development of several immunomodulatory agents aimed at enhancing the systemic antitumor immune response. One such method is the use of T cells that are genetically engineered to express chimeric antigen receptors (CARs). The remarkable success of this approach in advanced hematologic malignancies has garnered much enthusiasm for using this novel tool in treating other cancers. However, multiple challenges have hampered the application of this therapy to a broader set of solid tumors, most notably lung cancer. Immunotherapy has already shown great success in lung cancer, and is now the first-line treatment in PD-L1 expressing metastatic disease. Given the mounting evidence that radiation therapy plays a crucial role in amplifying the immune response elicited by immunomodulatory agents, there is potential for radiation to help in overcoming some of these challenges. In this review, we describe the basic principles of CAR T cell therapy and examine its successes and challenges to date. We then discuss the preclinical and clinical data supporting the use of radiation with immunomodulatory agents with a focus on preclinical rationale for combining CAR T cells and radiation therapy in future experiments with a focus on lung cancer.

AB - An increasing appreciation for the role of the immune system in targeting cancer cells over the last decade has led to the development of several immunomodulatory agents aimed at enhancing the systemic antitumor immune response. One such method is the use of T cells that are genetically engineered to express chimeric antigen receptors (CARs). The remarkable success of this approach in advanced hematologic malignancies has garnered much enthusiasm for using this novel tool in treating other cancers. However, multiple challenges have hampered the application of this therapy to a broader set of solid tumors, most notably lung cancer. Immunotherapy has already shown great success in lung cancer, and is now the first-line treatment in PD-L1 expressing metastatic disease. Given the mounting evidence that radiation therapy plays a crucial role in amplifying the immune response elicited by immunomodulatory agents, there is potential for radiation to help in overcoming some of these challenges. In this review, we describe the basic principles of CAR T cell therapy and examine its successes and challenges to date. We then discuss the preclinical and clinical data supporting the use of radiation with immunomodulatory agents with a focus on preclinical rationale for combining CAR T cells and radiation therapy in future experiments with a focus on lung cancer.

KW - Chimeric antigen receptor T cells (CAR T cells)

KW - Immunotherapy

KW - Radiation therap

UR - http://www.scopus.com/inward/record.url?scp=85018347154&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85018347154&partnerID=8YFLogxK

U2 - 10.21037/tlcr.2017.03.07

DO - 10.21037/tlcr.2017.03.07

M3 - Review article

AN - SCOPUS:85018347154

VL - 6

SP - 159

EP - 168

JO - Translational Lung Cancer Research

JF - Translational Lung Cancer Research

SN - 2226-4477

IS - 2

ER -